“The 340B Drug Pricing Program has weathered attacks from different health care actors for years. Just months after the outbreak of the COVID-19 pandemic, manufacturers launched attacks by refusing to sell 340B-priced drugs to health centers that use contract pharmacies to increase patient access,” writes Elizabeth Linderbaum, Deputy Director of Regulatory Affairs, in a recent NACHC blog post. “This combination of manufacturer restrictions, alongside existing discriminatory contracting actions taken by drug middlemen, known as pharmacy benefit managers, has severely threatened the stability of the 340B program for health centers.”
NACHC recently surveyed health centers to better understand the impact of these restrictions on health centers and highlight the importance of the 340B program. To read more, click here.